<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623595</url>
  </required_header>
  <id_info>
    <org_study_id>CHX-65</org_study_id>
    <nct_id>NCT02623595</nct_id>
  </id_info>
  <brief_title>A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy</brief_title>
  <official_title>A Prospective Single-arm Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT)
      combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is
      safe, effective in the treatment of stage IV NSCLC patients who failed in second-line
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in one
      cycle.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating
      factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another
      metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
      Efficacy evaluation,especially abscopal effect evaluation, will be conducted at the end of
      therapy and every month after that. Adverse events will be recorded according to NCI-CTC
      version 4.03.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>abscopal effect rate</measure>
    <time_frame>at the time point of 4 weeks after completion of rhGM-CSF</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>All adverse events will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abscopal effect rate</measure>
    <time_frame>at the time point of 2 months after completion of rhGM-CSF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>All treatment-related adverse events will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immune-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>All Immune-related adverse events will be recorded</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total T cells count in peripheral blood</measure>
    <time_frame>pre-treatment,1, 2, 3, 6, 12 months after completion of rhGM-CSF</time_frame>
    <description>To assess the absolute number of T cells in per milliliter peripheral blood pre- and post-therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute number of CD4+T, CD8+T and regulatory T cells</measure>
    <time_frame>pre-treatment,1, 2, 3, 6, 12 months after completion of rhGM-CSF</time_frame>
    <description>To assess ratio of effector T cells: regulatory T cells in per milliliter peripheral blood pre- and post-therapy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>SBRT+GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy</intervention_name>
    <description>A type of radiation therapy</description>
    <arm_group_label>SBRT+GM-CSF</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>SABR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF</intervention_name>
    <description>Immune modulating agents</description>
    <arm_group_label>SBRT+GM-CSF</arm_group_label>
    <other_name>Recombined human granulocyte-macrophage colony stimulating factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven non-small-cell lung cancer.

          2. Stage IV according to UICC stage system(version 7,2009).

          3. Progression after standard second-line chemotherapy.

          4. At least Three evaluable lesions among which at least two must be suitable for SBRT.

          5. ECOG performance status 0-2.

          6. Expected lifespan ≥3 months.

          7. Stable lab values:

             Hematological: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L,
             Hemoglobin ≥9 g/dL Renal: Creatinine OR Measured or calculated creatinine clearance
             (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or
             CrCl) ≤1.5× the upper limit of normal (ULN) OR ≥60 mL/min for patient with creatinine
             levels &gt;1.5× institutional ULN Hepatic: Total bilirubin ≤1.5×ULN OR Direct bilirubin
             ≤ULN for patients with total bilirubin levels &gt;1.5×ULN, Aspartate aminotransferase
             (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for patients with liver
             metastases ,globulin≥20 g/L, albumin≥30 g/L.

          8. Female subjects must have a negative urine or serum pregnancy test within 72 hours
             prior to taking study drug if of childbearing potential.

          9. Able to understand and give written informed consent and comply with study procedures.

        Exclusion criteria:

          1. Any unstable systemic disease, including active infection, uncontrolled high blood
             pressure, unstable angina, newly observed angina pectoris within the past 3 months,
             congestive heart failure (New York heart association (NYHA) class II or higher),
             myocardial infarction onset six months before included into the group, and severe
             arrhythmia, liver, kidney, or metabolic disease in need of drug therapy.

          2. Any clinical evidence suggests moderately severe chronic obstructive pulmonary disease
             (COPD) - [With COPD history or related risk factors, FEV1 / FVC &lt; 70%, FEV1 &lt; 80%
             estimated value, with or without chronic cough, sputum, dyspnea symptoms), active
             interstitial lung disease - ILD (FEV1 / FVC &lt; 70%, FEV1 &lt; 80% estimated value, carbon
             monoxide diffusion capacity in lung - DLCO &lt; 40%, and high resolution CT (HRCT)
             confirmed as the diffuse pulmonary interstitial lesions] and other active pulmonary
             disease.

          3. Previously diagnosed with autoimmune diseases, including but not limited to systemic
             lupus erythematous, rheumatoid arthritis, systemic vasculitis, scleroderma,
             dermatomyositis, autoimmune hemolytic anemia and autoimmune liver disease, autoimmune
             thyroiditis.

          4. Human immunodeficiency virus (HIV) infection.

          5. Women in pregnancy or lactation .

          6. Medicine abusers(including alcohol, drugs or other addictive drugs abusers).

          7. Patients with mental illness, considered as &quot;can't fully understand the issues of this
             research&quot;.

          8. Cancer history within 5 years apart from NSCLC before enrollment.

          9. Histologically confirmed small cell carcinoma or other non NSCLC compositions in the
             cancer tissue.

         10. Cancer treatment within 4 weeks, including but not limited to palliative surgery
             ,radiotherapy, chemotherapy and target therapy.

         11. Tumor related immunotherapy within 1 year, including but not limited to immune cell
             therapy, tumor vaccine therapy, immune check-point monoclonal antibody related
             treatment, and cytokines treatment except for GM-CSF.

         12. Allergy of rhGM-CSF and its accessories.

         13. Contraindications to GM-CSF treatment.

         14. Patients with unilateral lung.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Conghua Xie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Conghua Xie, MD, PhD</last_name>
    <phone>+86 27 67812607</phone>
    <email>chxie_65@whu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junhong Zhang, MD</last_name>
    <phone>+86 27 67812607</phone>
    <email>zjhzhongnan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan hospital of Wuhan university</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyuan Wu, PhD</last_name>
      <phone>+86 2767812668</phone>
      <email>znyylcsy@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.znhospital.cn/</url>
    <description>Official website</description>
  </link>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1685-93. doi: 10.1097/JTO.0000000000000686. Review.</citation>
    <PMID>26484629</PMID>
  </reference>
  <reference>
    <citation>Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, Hommura F, Nishimura T, Nishimura M. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 2008 Feb;99(2):361-7. doi: 10.1111/j.1349-7006.2007.00664.x. Epub 2008 Jan 14.</citation>
    <PMID>18201271</PMID>
  </reference>
  <reference>
    <citation>Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013 Jul;24(7):1813-21. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27.</citation>
    <PMID>23535954</PMID>
  </reference>
  <reference>
    <citation>Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.</citation>
    <PMID>25754329</PMID>
  </reference>
  <reference>
    <citation>Younes E, Haas GP, Dezso B, Ali E, Maughan RL, Kukuruga MA, Montecillo E, Pontes JE, Hillman GG. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol. 1995 Oct 15;165(2):243-51.</citation>
    <PMID>7553889</PMID>
  </reference>
  <reference>
    <citation>Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013 Dec;1(6):365-72. doi: 10.1158/2326-6066.CIR-13-0115.</citation>
    <PMID>24563870</PMID>
  </reference>
  <reference>
    <citation>Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012 Dec;5(6):404-7. Epub 2012 Dec 1.</citation>
    <PMID>23323154</PMID>
  </reference>
  <reference>
    <citation>Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.</citation>
    <PMID>26095785</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>May 30, 2016</last_update_submitted>
  <last_update_submitted_qc>May 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>Conghua Xie,MD,PhD</investigator_full_name>
    <investigator_title>Professor,MD,PhD,Director of Department of Radiation and Medical Oncology,Zhongnan Hospital</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>abscopal effect</keyword>
  <keyword>safety</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data of tumor response, abscopal effect rate and survival time will be available within 4 months of study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

